We're recruiting a Research Associate to join our Bioprocess Development team. This is a wet lab role ideally suited for someone graduating college this spring who is excited to join a team pioneering a new therapeutic modality
Check it out! 👇
www.aiproteins.com/open-positio...
I had a great time nerding out about protein design with @nickpolizzi.bsky.social, and an enormous thanks to @biotechtv.bsky.social and @massbio.bsky.social for hosting us!
www.biotechtv.com/post/chris-b...
Speaking as someone who had a career in academia before industry - there are many things I love about academia, but my job satisfaction is higher in industry.
I hope things get better for all my friends in academia, because switching isn't the solution for everyone.
www.nature.com/articles/d41...
We've got Jeff Gray (graylab.jhu.edu) coming to present this month!!
Wednesday, February 25th 2026, starting at 7pm EST in Room 181, Building 68, @MIT
"Antibody language models vs. biology; protein docking denoising diffusion models vs. physics"
bpdmc.org
Thanks for the fun conversation Ingmar Schuster, and for the opportunity to share more about what we're building at @aiproteins.com!
youtu.be/7O0s5AY46U0
I appreciate all the congratulations for our Series A! I also want to make sure we don't forget an important truth
Funding is not the finish line.
We're grateful for the resources we have, and my promise is that we'll continue to do everything in our power to make a difference
The next chapter for AI Proteins @aiproteins.com is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by Mission BioCapital and Santé Ventures.
endpoints.news/boston-biote...
Now, we’re using these capabilities to develop purpose-built #miniprotein medicines designed to match the complexity of human disease.
This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.
In this talk, I explain how our #miniproteins can interact with as many targets as needed to deliver the exact therapeutic outcome that patients require. This level of sophistication is unprecedented and will impact indications across oncology, inflammation, and beyond.
To truly control biology, we need medicines that can engage multiple targets simultaneously, but traditional modalities like small molecules and antibodies struggle to do this.
Biology is dizzyingly complex, and yet almost every medicine humanity has ever made acts on a single target in the body. Just a handful can interact with two distinct targets, and these are some of the most exciting treatments to enter the clinic in the past decade.
My new @ted.com talk from the main stage just went live!
go.ted.com/chrisbahl
🧵👇
Join us in Room 181, Building 68 @mit.edu on October 22nd 2025 @ 7pm EDT to see @grocklin.bsky.social present a mind blowing amount of data and learn what becomes possible at this scale
"Predicting protein folding stability and aggregation propensity using large-scale experiments"
bpdmc.org
We're looking for a mass spec expert to join our team at @aiproteins.com! This position is ideal for a freshly-minted PhD grad (or someone who will graduate within the next 6 months or less), or a rockstar scientist who earned their skills on the job in biotech
🎥 Neste videocast produzido junto do @ieausp.bsky.social, tive uma conversa inspiradora com o Anderson Soares (UFG), @alexandre-cf.bsky.social e o @cdbahl.com sobre como a IA está moldando o futuro da biologia e da saúde humana. Assista aqui 👉 www.youtube.com/watch?v=qQbZ...
Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer!
www.businesswire.com/news/home/20...
It’s a privilege to be building @aiproteins.com together with James and our unbelievably talented and dedicated team of people, all striving to make a difference in the world through our technology
www.businesswire.com/news/home/20...
As our first CTO at @aiproteins.com, James will lead the continued acceleration of our platform capabilities in addition to the design, testing and optimization of many novel #miniprotein drug candidates
Our mission is to industrialize drug discovery to create programmable, #denovo protein-based medicines that help patients across a wide range of diseases
James has been one of the key architects of this vision since day one, and his insight and leadership these past ~4 years has shaped the discovery engine that powers @aiproteins.com today
What began as an idea — that we could scale de novo protein design — is now a fully-operational platform that integrates generative #AI with automated production and characterization in the wet lab
James joined my academic lab at the @ipiproteins.bsky.social in January of 2020 as a postdoc focused on #miniprotein de novo design and engineering. Less than 2 years later, James and I left academia together to found @aiproteins.com along with an incredible team of people from my former lab.
I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com!
🧵👇
This was a lot of fun - thanks so much @yossefbaidi.bsky.social and @fang-xie.bsky.social for the great conversation, and for your passion and excitement for biotech and entrepreneurship!
Super excited to share a new preprint from our lab on design of small-molecule binding proteins using neural networks! The paper has a bit of everything. A new graph neural network, new design algorithms, and experimental validation. www.biorxiv.org/content/10.1...
🧵🧪
#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l
And most importantly, a huge thank you to the phenomenal team at @aiproteins.bsky.social
Your dedication, ingenuity, and relentless pursuit of innovation are the driving force behind the amazing work we do. It's a privilege to lead such a talented group and to share our achievements with the world
I'm so grateful to Lily James Olds, Leonie Hoerster and Allegra Pearl from TED Conferences for providing such incredible support
It was an honor to speak from the main stage at TED last week about our work at AI Proteins
Our mission is to design the next generation of therapeutics built from de novo #miniproteins, and this was an unbelievable opportunity to help shape the broader conversation about the future of biologics
